pSivida Corp. (PSDV) Reports a Q1 Loss
pSivida Corp. (NASDAQ: PSDV) reports a Q1 loss of $0.03 compared to a loss of $0.04 for the same period last year.
Revenues for the three months ended September 30, 2008 were $2.8 million compared to revenues of $103,000 for the comparable period of the prior fiscal year. Current quarter revenues were predominantly related to the Company's March 2008 amended collaboration agreement with Alimera Sciences, Inc.
"With cash of approximately $11.0 million at September 30, 2008, no debt, our current collaboration and licensing agreements and an expected filing of the NDA for Iluvien in early 2010, we believe we can fund our operations as currently conducted without accessing the capital markets through to receipt of the $25m milestone payment that is due if Iluvien is approved by the FDA."
pSivida Corp., formerly pSivida Limited., is a drug delivery company committed to the biomedical sector, with a primary focus on ophthalmology and oncology. [SM]
Revenues for the three months ended September 30, 2008 were $2.8 million compared to revenues of $103,000 for the comparable period of the prior fiscal year. Current quarter revenues were predominantly related to the Company's March 2008 amended collaboration agreement with Alimera Sciences, Inc.
"With cash of approximately $11.0 million at September 30, 2008, no debt, our current collaboration and licensing agreements and an expected filing of the NDA for Iluvien in early 2010, we believe we can fund our operations as currently conducted without accessing the capital markets through to receipt of the $25m milestone payment that is due if Iluvien is approved by the FDA."
pSivida Corp., formerly pSivida Limited., is a drug delivery company committed to the biomedical sector, with a primary focus on ophthalmology and oncology. [SM]
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Mentor Graphics Corp (MENT) Beats Q1 EPS View by 5c; Lifts FY13 Outlook
- Jiayuan.com (DATE) Reports In-Line Q1 EPS of 5c; Guides Q2 Revs
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
